Apply for the PhD Scholarship in Health Economics for Diabetes 1 August 2025 We are thrilled to announce Diabetes Australia, in partnership with Western Sydney University, will co-fund a PhD scholarship. This scholarship offers a unique opportunity for domestic candidates to contribute to critical research examining the economic burden of diabetes in Australia. Why does this research matter? Diabetes is a significant and growing concern in Australia, not just for those living with the condition but for society. Understanding the economic costs associated with diabetes, both direct and indirect, can provide invaluable insights that inform health policy decisions and guide strategic investments aimed at reducing the impact of this condition. What is the research? As a PhD candidate under this scholarship, you will engage in comprehensive research that explores: Direct healthcare costs associated with diabetes and its complications. Indirect costs including productivity loss, the financial burden on caregivers, and out-of-pocket expenses. Variations in costs influenced by factors such as payer, geographic location, diabetes type, population subgroups, and other relevant factors. What does the scholarship offer? The scholarship offers an attractive stipend and professional support package of up to $60,000 per annum for three years. This generous support allows you to focus on your research and professional development with reduced stress of financial burdens. Who should apply? We invite applications from individuals from a range of backgrounds who are keen to apply their skills to address key issues in the economics of diabetes. How to apply Start your application today by clicking the link below for more information about this opportunity, including eligibility criteria and the application process. All applications must be submitted by 10 August 2025. Submit your application today.
News 24 July 2026 GLP-1 RA safety update for rare but severe eye disorders The Therapeutic Goods Administration has updated GLP-1 RA product warnings because of their potential to cause a rare but severe eye disorder. The glucagon-like peptide-1 receptor agonist... Continue Reading
News 20 July 2026 Response to media reports from 60 Minutes, The Sydney Morning Herald, and The Age regarding regulation of diabetes technologies The safety of people living with diabetes must always come first. For many Australians, technologies such as insulin pumps and continuous glucose monitors are essential tools that help prevent dangerous high and low blood glucose levels, reduce the daily burden of living with diabetes and improve long-term health outcomes. For some individuals they can be life-changing or even life-saving. Continue Reading
Media releases 8 July 2026 Territory-led digital health innovation receives boost from national partnership A major funding boost will expand digital health solutions for complex care in the Northern Territory (NT), thanks to a joint investment from Diabetes Australia and Lilly Australia, in partnership with Menzies School of Health Research (Menzies). Continue Reading